Prashant Kumar

About

I am a research scientist working on the development of low-cost and stable vaccine formulations to extend global access of the vaccines. I am currently working on AAV based COVID-19, sIPV and Combination vaccine and Measles and Rubella, and Shigella vaccine projects at Vaccine Analytics and Formulation Center (VAFC) at KU, known for its excellent expertise in the field of vaccine development. My past projects include development of live attenuated RV3-BB rotavirus, non-replicating rotavirus vaccine (NRRV), HPV, Salmonella and Shigella Vaccines. Most of my current/past projects are in phase 1-3 clinical trials. My multidisciplinary background in bioprocessing, formulation development, analytical and biophysical characterization coupled with statistical design of experiments (DOE) helps in efficient process development and cost minimization needed to make these projects a success. My other research areas include scale-up, technology transfer, process characterization and validation. Committed to high standards of research, cross-functional teamwork, relationship building and scientific collaboration across multiple disciplines.

Websites:
(1) Vaccine Analytics and Formulation Center (VAFC), KU: http://vafc.ku.edu/
(2) Google Scholar: https://scholar.google.com/citations?user=uD3q_DcAAAAJ&hl=en
(3) Research Gate: https://www.researchgate.net/profile/Prashant-Kumar-311
(4) Publons: https://publons.com/researcher/1316285/prashant-kumar/

Employment

• University of Kansas Scientific Assistant Director
  2022 - Present
• University of Kansas Senior Scientist
  2019 - 2022
• University of Kansas Associate Researcher
  2017 - 2019
• University of Kansas Postdoctoral Researcher
  2017 - 2017
• University of Kansas Postdoctoral Researcher
  2015 - 2017

Education

• Institute of Chemical Technology PhD Tech in Bioprocess Technology
  2009 - 2015
• Institute of Chemical Technology Master's of Technology in Bioprocess Technology
  2007 - 2009
• Padmashree Dr DY Patil University Bachelor's of Technology in Biotechnology
  2003 - 2007

Projects & Funding

Projects & funding information is unavailable.

Publications (28)

• Development of a New Lyophilized Live-Attenuated Measles-Rubella (MR) Vaccine Formulation Designed for Lower Cost Production in Africa
  2026 DOI: 10.12688/verixiv.3646.1
  +Save
• Case Study on Formulating a Multidose Lyophilized Measles-Rubella (MR) Vaccine Candidate for Local Manufacturing in Africa: Lab-Scale Results and Lessons-Learned for Future Technology Transfer
  2026 DOI: 10.12688/verixiv.3696.1
  +Save
• Compatibility and Stability of a Shigella Polysaccharide—Protein Conjugate Antigen Formulated with Aluminum Salt and CpG 1018® Adjuvants
  Vaccines 2025 DOI: 10.3390/vaccines14010010
  +Save
• Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate
  Molecular Therapy - Methods & Clinical Development 2023 DOI: 10.1016/j.omtm.2023.06.004
  +Save
• Analytical Considerations to Support Expeditious Formulation Development of Vaccines
  Bioanalysis 2023 DOI: 10.4155/bio-2023-0090
  +Save
• Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate
  2023 DOI: 10.1101/2023.03.10.532114
  +Save
• Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations
  Journal of Pharmaceutical Sciences 2023 DOI: 10.1016/j.xphs.2022.09.001
  +Save
• Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication
  Human Vaccines & Immunotherapeutics 2022 DOI: 10.1080/21645515.2022.2154100
  +Save
• Novel Approaches for Overcoming Biological Barriers
  Pharmaceutics 2022 DOI: 10.3390/pharmaceutics14091851
  +Save
• Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency
  Vaccine 2022 DOI: 10.1016/j.vaccine.2022.07.017
  +Save